Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the U.S. Food and Drug Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) in August 2011, merely 4 years after the first publication of ALK-rearranged NSCLC. The crizotinib approval...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ou, Sai-Hong Ignatius, Bartlett, Cynthia Huang, Mino-Kenudson, Mari, Cui, Jean, Iafrate, A. John
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Academia-Pharma Intersect
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500356/
https://ncbi.nlm.nih.gov/pubmed/22989574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0311
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados